

Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare

Osaka, Japan, November 14, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that ViiV Healthcare (Head Office: London; Chief Executive Officer: Dr. Dominique Limet) has disclosed data from VIKING-3 study, which is one of the phase III studies which will be part of regulatory filings of the investigational integrase inhibitor, dolutegravir.

Among four phase III studies of dolutegravir, data from the SPRING-2 and SINGLE studies in treatment-naïve patients were previously disclosed (in April and July 2012). This time, ViiV Healthcare has disclosed data from the VIKING-3 study in HIV-1 infected integrase inhibitor-resistant adults. VIKING-3 is the first of two studies in treatment-experienced patients and is being presented at the Eleventh International Congress on Drug Therapy in HIV Infection (HIV11) held in Glasgow, UK this week.

Shionogi is striving to maximize the full potential long-term value of dolutegravir and other integrase inhibitors in the portfolio as a shareholder of ViiV Healthcare.

Forward-looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications

Shionogi & Co., Ltd.

Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099